China’s BCI Boom: How Far Ahead Is It?

While Elon Musk’s Neuralink often positions itself as the “pioneering” force in brain-computer interfaces (BCIs), China’s BCI industry is rapidly transitioning from research and development to large-scale commercialization. A new generation of startups is aggressively pursuing the commercialization of both implantable and non-invasive BCIs, fueled by robust policy support, expanding clinical trials, and increasing investor confidence. This surge is driven by visionaries like Phoenix Peng, the founder of both NeuroXess, a BCI implant manufacturer, and Gestala, a startup specializing in non-invasive ultrasound BCIs.

The Rise of China’s BCI Industry: A Four-Factor Framework

Peng believes the market potential is immense, extending beyond medical applications like “treating disease” to “human augmentation.” He envisions a future where neuroscience and artificial intelligence (AI) converge, creating direct, high-bandwidth connections between the human brain and AI. “BCI will serve as the ultimate bridge between carbon-based and silicon-based intelligence,” Peng stated. “While this may sound distant, it represents an unimaginably vast market in the future.” But in the immediate future – the next three to five years – BCI applications are likely to remain concentrated in healthcare, with the market projected to reach a multi-billion dollar scale as insurance coverage expands.

In August 2025, China’s Ministry of Industry and Information Technology, along with six other agencies, released a national roadmap to accelerate BCI development. This plan outlines key technical milestones for 2027, the establishment of common industry standards, and the creation of a complete supply chain by 2030, with the overarching goal of fostering globally competitive BCI companies and supporting specialized firms.

According to Peng, four key factors are driving China’s rapid progress in the BCI sector:

• Strong Policy Support: Cross-departmental collaboration is streamlining technical standards and medical reimbursement processes. In December 2025, China announced a 11.6 billion yuan ($165 million) brain science fund to support BCI companies throughout the entire lifecycle, from research to commercialization.
• Vast Clinical Resources: China boasts large patient populations and lower research costs, accelerating clinical trials. The national health insurance system facilitates quicker commercialization upon state approval, a contrast to the U.S. where private insurers require individual approvals.
• Mature Industrial Manufacturing: China’s established manufacturing capabilities in semiconductors, AI, and medical hardware support rapid R&D and prototyping.
• Strategic Investment: Both state-led funds and private capital are flowing into the market, driven by national initiatives.

Recent Investment and Key Players

Recent investment activity highlights the growing momentum. Shanghai-based StairMed Technology secured $48 million (350 million yuan) in Series B funding in February 2025. BrainCo, a neurotech company developing non-invasive BCIs and bionic limbs, has reportedly filed for a Hong Kong IPO after raising $287 million (2 billion yuan) earlier in the year. Peng’s Gestala, launched in January, is currently in discussions with investors to finalize an angel round.

These startups are poised to challenge established U.S. leaders like Neuralink, Synchron, and Paradromics. Key players in China include NeuroXess, Neuracle, NeuralMatrix, BrainCo, Bo Rui Kang Tech, Aoyi Tech, Brainland Tech, and Zhiran Medical, each pursuing diverse approaches ranging from implantable flexible interfaces to non-invasive brain-computer technologies.

Market projections indicate that China’s BCI market is expected to exceed $530 million (3.8 billion yuan) in 2025, up from 3.2 billion yuan in 2024, with forecasts estimating a value of over 120 billion yuan by 2040.

Invasive vs. Non-Invasive BCIs: A Comparative Overview

BCIs are broadly categorized into two main types. Invasive electrophysiological BCIs, such as those developed by NeuroXess and Neuralink, involve implanting electrodes directly into the brain to capture precise neuron-level signals. However, this approach carries inherent surgical risks. Non-invasive systems, like those from NeuroSky and BrainCo, prioritize safety and ease of use, albeit with some trade-offs in precision.

The field is expanding beyond these traditional approaches, with emerging technologies like ultrasound, magnetoencephalography imaging, transcranial magnetic stimulation, optical methods, and hybrid BCIs offering new tools for reading and influencing brain activity.

Addressing Adoption Barriers with Non-Invasive Technology

Startup founders recognize that non-invasive technology can overcome significant adoption barriers. Many individuals are hesitant to undergo brain surgery to have a device implanted. This makes non-invasive solutions more accessible and commercially scalable.

Ultrasound BCIs, pioneered by companies like Merge Labs (backed by OpenAI) and Gestala, are targeting prevalent conditions such as chronic pain, stroke, and depression. As non-invasive solutions, these technologies are more readily accepted by patients.

Gestala anticipates launching its first-generation product in Q3. Early clinical trials have demonstrated promising results, with a single session reducing pain scores by 50%, with effects lasting one to two weeks, according to Peng.

Investment Strategies and Future Outlook

HongShan Capital (formerly Sequoia China) has invested in Zhiran Medical, a startup founded in 2022 focused on improving the long-term performance of brain implants. The company utilizes flexible, high-throughput electrodes to minimize inflammation and signal loss associated with rigid implants.

Yang Yunxia, a partner at HongShan Capital, emphasizes the importance of practical application and commercial viability in investment decisions. “Some technologies may look cutting-edge but far from practical application,” Yunxia wrote in a blog post. She contends that others, while commercially viable, may face “high costs” or significant technical hurdles. Ultimately, investment hinges on the belief that a product can be developed into a sustainable business.

Navigating the Regulatory Landscape and Ethical Considerations

Over the next five years, industry experts anticipate that China’s BCI regulations will align more closely with international standards, particularly regarding regulatory approval and data sovereignty. Frameworks developed by organizations like the IEC and ISO, along with guidance from the U.S. Food and Drug Administration (FDA), are expected to serve as key references.

Chinese regulators are also expected to increase oversight of invasive devices and the data they generate, while simultaneously streamlining the approval process for non-invasive technologies.

Addressing the ethical implications of brain-implanted or manipulating devices is also a priority. China plans to strengthen informed-consent requirements, broaden ethics review beyond medical applications, and work towards unified technical standards for clinical evaluation. The future of BCIs in China is not just about technological advancement, but also about responsible innovation and ethical considerations.